Barry Schweitzer '82
Barry Schweitzer, Ph.D. joined the Technology Transfer Office as Senior Business Development and Licensing Manager in 2019, after 20+ years of experience in management and leadership positions in the biotech industry. Prior to joining Dartmouth, he was a Venture Partner at Elm Street Ventures, a seed and early stage venture capital firm based in New Haven, CT, where he led investments in the life sciences. He also served on the board of the Elm City Innovation Collaborative, an organization supported by the State of Connecticut to promote, connect, and enable New Haven’s diverse innovation ecosystem, and was an Entrepreneur in Residence at Yale University and the University of Connecticut. A serial entrepreneur, Barry was co-founder and CEO of Glygenix Therapeutics, Inc., a gene therapy company developing treatments for orphan diseases in children, and helped to start up two Yale biotech spin-off companies (Molecular Staging and Protometrix, Inc., acquired by Invitrogen Corporation.) He was previously an R&D leader at Life Technologies, Inc, and a Principal at BLS Partners LLC, a management consulting firm. Prior to entering the biotechnology industry, Barry was an Assistant Professor in the Department of Chemistry at the University of Central Florida, a Leukemia Society Special Fellow in the Department of Pediatrics at Yale School of Medicine, and a post-doctoral fellow at the Memorial Sloan-Kettering Cancer Institute after receiving his Ph.D. in Pharmacology from Yale. Barry was happy to return to Dartmouth where he received his Bachelor’s degree in Biology. When he is not reading scientific publications on weekends he runs with his dogs, fly fishes or skis, and enjoys his new grandson.